User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Goal-directed treatment of osteoporosis in Europe

Primary tabs

Kanis, J.A. McCloskey, E. Branco, J. Brandi, M.-L. Dennison, E. Devogelaer, Jean-Pierre [UCL] Rizzoli, R.

Despite the proven predictive ability of bone mineral density, Fracture Risk Assessment Tool (FRAX®), bone turnover markers, and fracture for osteoporotic fracture, their use as targets for treatment of osteoporosis is limited. INTRODUCTION: Treat-to-target is a strategy applied in several fields of medicine and has recently become an area of interest in the management of osteoporosis. Its role in this setting remains controversial. This article was prepared following a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group meeting convened under the auspices of the International Osteoporosis Foundation (IOF) to discuss the feasibility of applying such a strategy in osteoporosis in Europe. METHODS: Potential targets range from the absence of an incident fracture to fixed levels of bone mineral density (BMD), a desired FRAX® score, a specified level of bone turnover markers or indeed changes in any one or a combination of these parameters. RESULTS: Despite the proven predictive ability of all of these variables for fracture (particularly BMD and FRAX), their use as targets remains limited due to low sensitivity, the influence of confounders and current lack of evidence that targets can be consistently reached. CONCLUSION: ESCEO considers that it is not currently feasible to apply a treat-to-target strategy in osteoporosis, though it did identify a need to continue to improve the targeting of treatment to those at higher risk (target-to-treat strategy) and a number of issues for the research agenda. These include international consensus on intervention thresholds and definition of treatment failure, further exploration of the relationship between fracture and BMD, and FRAX and treatment efficacy and investigation of the potential of short-term targets to improve adherence

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "Osteoporosis International : with other metabolic bone diseases" - Vol. 25, no. 11, p. 2533-2543 (2014)
Peer reviewed yes
Publisher Springer U K ((United Kingdom) London)
issn 0937-941X
e-issn 1433-2965
Publication status Publié
Affiliations UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales
UCL - (SLuc) Service de rhumatologie
Links
  1. Lewiecki E. Michael, Cummings Steven R., Cosman Felicia, Treat-to-target for Osteoporosis: Is Now the Time?, 10.1210/jc.2012-3680
  2. Cummings Steven R, Cosman Felicia, Eastell Richard, Reid Ian R, Mehta Mona, Lewiecki E Michael, Goal-directed treatment of osteoporosis, 10.1002/jbmr.1854
  3. McCloskey Eugene, Leslie William D, Goal-directed therapy in osteoporosis, 10.1002/jbmr.1859
  4. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis, 10.1016/0002-9343(93)90218-e
  5. Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health care level. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK, Sheffield, Technical Report
  6. Staessen Jan A, Wang Ji-Guang, Thijs Lutgarde, Cardiovascular protection and blood pressure reduction: a meta-analysis, 10.1016/s0140-6736(01)06411-x
  7. 2013 ESH/ESC Guidelines for the management of arterial hypertension : The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 10.1093/eurheartj/eht151
  8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 10.1016/s0140-6736(98)07019-6
  9. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, 10.1056/nejm199309303291401
  10. Inzucchi S. E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M., Peters A. L., Tsapas A., Wender R., Matthews D. R., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), 10.1007/s00125-012-2534-0
  11. IDF Clinical Guidelines Task Force (2013) Global Guideline for Type 2 Diabetes. www.idf.com . Accessed 17 July 2013
  12. Cannon Christopher P., The IDEAL Cholesterol : Lower Is Better, 10.1001/jama.294.19.2492
  13. Catapano AL, Reiner Z, De BG et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(Suppl 1):S1–44
  14. McAlister Finlay A, van Diepen Sean, Padwal Rajdeep S, Johnson Jeffrey A, Majumdar Sumit R, How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?, 10.1371/journal.pmed.0040250
  15. Hayward R. A., Krumholz H. M., Three Reasons to Abandon Low-Density Lipoprotein Targets: An Open Letter to the Adult Treatment Panel IV of the National Institutes of Health, 10.1161/circoutcomes.111.964676
  16. Ledford Heidi, Cholesterol limits lose their lustre, 10.1038/494410a
  17. Krumholz H. M., Target cardiovascular risk rather than cholesterol concentration, 10.1136/bmj.f7110
  18. National Institute for Health and Clinical Excellence (NICE)—British Hypertension Society (BHS) (2006) Hypertension: management of hypertension in adults in primary care. www.nice.org.uk/CG034guidance . Accessed 31 July 2013
  19. Zanchetti Alberto, Grassi Guido, Mancia Giuseppe, When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal : , 10.1097/hjh.0b013e32832aa6b5
  20. National Institute for Health and Clinical Excellence (2011) Hypertension: The clinical management of primary hypertension in adults. August 2011. http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf . Accessed 13 Jan 2012
  21. Goff DC Jr., Lloyd-Jones DM, Bennett G et al. (2013) 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation
  22. Stone NJ, Robinson J, Lichtenstein AH et al. (2013) 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
  23. Kane SP (2014) Pooled cohort equations to predict 10-year risk of first cardiovascular event. http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx . Accessed 7 April 2014
  24. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B., Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, 10.2337/dc08-9025
  25. Smolen J. S., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J. J., Haraoui B., Kalden J., Keystone E. C., Kvien T. K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D., , Treating rheumatoid arthritis to target: recommendations of an international task force, 10.1136/ard.2009.123919
  26. Schoels M., Wong J., Scott D. L., Zink A., Richards P., Landewe R., Smolen J. S., Aletaha D., Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, 10.1136/ard.2009.126714
  27. Feldmann Marc, Maini Ravinder N, TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases, 10.1038/nm939
  28. Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Porter Duncan, Kincaid Wilma, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, 10.1016/s0140-6736(04)16676-2
  29. Diez-Perez A., , Adachi J. D., Agnusdei D., Bilezikian J. P., Compston J. E., Cummings S. R., Eastell R., Eriksen E. F., Gonzalez-Macias J., Liberman U. A., Wahl D. A., Seeman E., Kanis J. A., Cooper C., Treatment failure in osteoporosis, 10.1007/s00198-012-2093-8
  30. Marshall D., Johnell O., Wedel H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, 10.1136/bmj.312.7041.1254
  31. Johnell Olof, Kanis John A, Oden Anders, Johansson Helena, De Laet Chris, Delmas Pierre, Eisman John A, Fujiwara Seiko, Kroger Heikki, Mellstrom Dan, Meunier Pierre J, Melton L Joseph, O'Neill Terry, Pols Huibert, Reeve Jonathan, Silman Alan, Tenenhouse Alan, Predictive Value of BMD for Hip and Other Fractures, 10.1359/jbmr.050304
  32. Kanis J. A., Johnell O., Oden A., Jonsson B., Dawson A., Dere W., Risk of Hip Fracture Derived from Relative Risks: An Analysis Applied to the Population of Sweden : , 10.1007/pl00004173
  33. Kanis J. A., Johnell O., Oden A., De Laet C., Dawson A., Jonsson B., Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds, 10.1007/s001980170006
  34. Kanis J. A., , Odén A., McCloskey E. V., Johansson H., Wahl D. A., Cooper C., A systematic review of hip fracture incidence and probability of fracture worldwide, 10.1007/s00198-012-1964-3
  35. Kanis J. A., , McCloskey E. V., Johansson H., Cooper C., Rizzoli R., Reginster J.-Y., European guidance for the diagnosis and management of osteoporosis in postmenopausal women, 10.1007/s00198-012-2074-y
  36. Ferrari S, Adachi J, Lippuner K et al (2013) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Abstr J Bone Miner Res 28:1017
  37. Hochberg Marc C., Greenspan Susan, Wasnich Richard D., Miller Paul, Thompson Desmond E., Ross Philip D., Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents, 10.1210/jcem.87.4.8415
  38. Bjarnason N. H., Sarkar S., Duong T., Mitlak B., Delmas P. D., Christiansen C., Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis, 10.1007/s001980170020
  39. Bauer Douglas C, Black Dennis M, Garnero Patrick, Hochberg Marc, Ott Susan, Orloff John, Thompson Desmond E, Ewing Susan K, Delmas Pierre D, , Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial, 10.1359/jbmr.040512
  40. Eastell R, Barton I, Hannon Ra, Chines A, Garnero P, Delmas Pd, Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate, 10.1359/jbmr.2003.18.6.1051
  41. Jacques Richard M, Boonen Steven, Cosman Felicia, Reid Ian R, Bauer Douglas C, Black Dennis M, Eastell Richard, Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT), 10.1002/jbmr.1644
  42. Austin Matthew, Yang Yu-Ching, Vittinghoff Eric, Adami Silvano, Boonen Steven, Bauer Douglas C, Bianchi Gerolamo, Bolognese Michael A, Christiansen Claus, Eastell Richard, Grauer Andreas, Hawkins Federico, Kendler David L, Oliveri Beatriz, McClung Michael R, Reid Ian R, Siris Ethel S, Zanchetta Jose, Zerbini Cristiano AF, Libanati Cesar, Cummings Steven R, , Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, 10.1002/jbmr.1472
  43. Bruyere Olivier, Roux Christian, Detilleux Johann, Slosman Daniel O., Spector Tim D., Fardellone Patrice, Brixen Kim, Devogelaer Jean-Pierre, Diaz-Curiel Manuel, Albanese Carlina, Kaufman Jean-Marc, Pors-Nielsen Stig, Reginster Jean-Yves, Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate, 10.1210/jc.2006-2758
  44. Sarkar Somnath, Mitlak Bruce H., Wong Mayme, Stock John L., Black Dennis M., Harper Kristine D., Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy, 10.1359/jbmr.2002.17.1.1
  45. Li Zhengqing, Meredith Michael P., Hoseyni Mohammad S., A method to assess the proportion of treatment effect explained by a surrogate endpoint, 10.1002/sim.984
  46. Chen Peiqi, Miller Paul D, Recker Robert, Resch Heinrich, Rana Asad, Pavo Imre, Sipos Adrien A, Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis, 10.1359/jbmr.070413
  47. Rosen Clifford J, Hochberg Marc C, Bonnick Sydney L, McClung Michael, Miller Paul, Broy Susan, Kagan Risa, Chen Erluo, Petruschke Richard A, Thompson Desmond E, de Papp Anne E, Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study, 10.1359/jbmr.040920
  48. Vasikaran S., , Eastell R., Bruyère O., Foldes A. J., Garnero P., Griesmacher A., McClung M., Morris H. A., Silverman S., Trenti T., Wahl D. A., Cooper C., Kanis J. A., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards, 10.1007/s00198-010-1501-1
  49. Johansson Helena, , Odén Anders, Kanis John A., McCloskey Eugene V., Morris Howard A., Cooper Cyrus, Vasikaran Samuel, A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture, 10.1007/s00223-014-9842-y
  50. Kanis J. A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., Burckhardt P., Cooper C., Christiansen C., Cummings S., Eisman J. A., Fujiwara S., Glüer C., Goltzman D., Hans D., Krieg M.-A., La Croix A., McCloskey E., Mellstrom D., Melton L. J., Pols H., Reeve J., Sanders K., Schott A-M., Silman A., Torgerson D., van Staa T., Watts N. B., Yoshimura N., The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, 10.1007/s00198-007-0343-y
  51. Arlot Monique, Meunier Pierre J, Boivin Georges, Haddock Lillian, Tamayo Juan, Correa-Rotter Ricardo, Jasqui Salomón, Donley David W, Dalsky Gail P, Martin Javier San, Eriksen Erik Fink, Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters, 10.1359/jbmr.050309
  52. Ettinger Bruce, Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial, 10.1001/jama.282.7.637
  53. Reginster J.-Y, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J, Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk, 10.1016/j.bone.2003.10.004
  54. Garnero P., Hausherr E., Chapuy M.-C., Marcelli C., Grandjean H., Muller C., Cormier C., Bréart G., Meunier P.J., Delmas Pierre D., Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study, 10.1002/jbmr.5650111021
  55. Bergmann P., Body J.-J., Boonen S., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., Reginster J.-Y., Gangji V., , Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club, 10.1111/j.1742-1241.2008.01911.x
  56. Marcus Robert, Wang Ouhong, Satterwhite Julie, Mitlak Bruce, The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis, 10.1359/jbmr.2003.18.1.18
  57. Neer Robert M., Arnaud Claude D., Zanchetta Jose R., Prince Richard, Gaich Gregory A., Reginster Jean-Yves, Hodsman Anthony B., Eriksen Erik F., Ish-Shalom Sophia, Genant Harry K., Wang Ouhong, Mellström Dan, Oefjord Erik S., Marcinowska-Suchowierska Ewa, Salmi Jorma, Mulder Henk, Halse Johan, Sawicki Andrzej Z., Mitlak Bruce H., Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, 10.1056/nejm200105103441904
  58. Jiang Yebin, Zhao Jenny J, Mitlak Bruce H, Wang Ouhong, Genant Harry K, Eriksen Erik F, Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure, 10.1359/jbmr.2003.18.11.1932
  59. Saag Kenneth G., Shane Elizabeth, Boonen Steven, Marín Fernando, Donley David W., Taylor Kathleen A., Dalsky Gail P., Marcus Robert, Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, 10.1056/nejmoa071408
  60. Arlot Monique E, Jiang Yebin, Genant Harry K, Zhao Jenny, Burt-Pichat Brigitte, Roux Jean-Paul, Delmas Pierre D, Meunier Pierre J, Histomorphometric and μCT Analysis of Bone Biopsies From Postmenopausal Osteoporotic Women Treated With Strontium Ranelate, 10.1359/jbmr.071012
  61. Rizzoli René, Laroche Michel, Krieg Marc-Antoine, Frieling Isolde, Thomas Thierry, Delmas Pierre, Felsenberg Dieter, Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis, 10.1007/s00296-010-1542-y
  62. Rizzoli R., Chapurlat R. D., Laroche J.-M., Krieg M. A., Thomas T., Frieling I., Boutroy S., Laib A., Bock O., Felsenberg D., Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis : Results of a 2-year study, 10.1007/s00198-011-1758-z
  63. Bala Yohann, Zebaze Roger, Ghasem-Zadeh Ali, Atkinson Elizabeth J, Iuliano Sandra, Peterson James M, Amin Shreyasee, Bjørnerem Åshild, Melton L Joseph, Johansson Helena, Kanis John A, Khosla Sundeep, Seeman Ego, Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures : CORTICAL POROSITY AND BONE FRAGILITY, 10.1002/jbmr.2167
  64. Silva Barbara C, Leslie William D, Resch Heinrich, Lamy Olivier, Lesnyak Olga, Binkley Neil, McCloskey Eugene V, Kanis John A, Bilezikian John P, Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image : TRABECULAR BONE SCORE, 10.1002/jbmr.2176
  65. Keaveny Tony M, L Bouxsein Mary, Theoretical Implications of the Biomechanical Fracture Threshold, 10.1359/jbmr.080406
  66. Keaveny Tony M, Donley David W, Hoffmann Paul F, Mitlak Bruce H, Glass Emmett V, San Martin Javier A, Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis, 10.1359/jbmr.061011
  67. Kopperdahl David L, Aspelund Thor, Hoffmann Paul F, Sigurdsson Sigurdur, Siggeirsdottir Kristin, Harris Tamara B, Gudnason Vilmundur, Keaveny Tony M, Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans : INCIDENT FRACTURE ASSESSMENT USING FEA OF CT SCANS, 10.1002/jbmr.2069
  68. Kanis John A., Borgstrom Frederik, De Laet Chris, Johansson Helena, Johnell Olof, Jonsson Bengt, Oden Anders, Zethraeus Niklas, Pfleger Bruce, Khaltaev Nikolai, Assessment of fracture risk, 10.1007/s00198-004-1780-5
  69. Kanis J. A., Johansson H., Oden A., McCloskey E. V., A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®, 10.1007/s00198-010-1474-0
  70. McCloskey Eugene V, Johansson Helena, Oden Anders, Austin Matt, Siris Ethel, Wang Andrea, Lewiecki E Michael, Lorenc Roman, Libanati Cesar, Kanis John A, Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX, 10.1002/jbmr.1606
  71. Kanis John A., Johansson Helena, Oden Anders, McCloskey Eugene V., A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®, 10.1016/j.bone.2010.06.009
  72. Kanis John A., Johansson Helena, Oden Anders, McCloskey Eugene V., Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®, 10.1016/j.bone.2009.02.014
  73. Donaldson Meghan G, Palermo Lisa, Ensrud Kristine E, Hochberg Marc C, Schousboe John T, Cummings Steven R, Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial, 10.1002/jbmr.1625
  74. Leslie William D, Lix Lisa M, Johansson Helena, Oden Anders, McCloskey Eugene, Kanis John A, , Does osteoporosis therapy invalidate FRAX for fracture prediction?, 10.1002/jbmr.1582
  75. Leslie William D, Majumdar Sumit R, Lix Lisa M, Morin Suzanne N, Johansson Helena, Odén Anders, McCloskey Eugene V, Kanis John A, Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study : FRAX FOR TREAT TO TARGET, 10.1002/jbmr.2151
  76. Canoui-Poitrine F., Jaglal S., Chapurlat R., Tainturier V., Colin C., Schott A.M., Has reimbursement of bone mineral density testing and anti-osteoporotic treatments improved management of osteoporosis in France?, 10.1016/j.bone.2010.06.026
  77. Jennings Lee A., Auerbach Andrew D., Maselli Judith, Pekow Penelope S., Lindenauer Peter K., Lee Sei J., Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture : [See editorial comments by Dr. Robert A. Adler, pp 762-764], 10.1111/j.1532-5415.2010.02769.x
  78. Hernlund E., Svedbom A., Ivergård M., Compston J., Cooper C., Stenmark J., McCloskey E. V., Jönsson B., Kanis J. A., Osteoporosis in the European Union: medical management, epidemiology and economic burden : A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA), 10.1007/s11657-013-0136-1
  79. Kanis J. A., Borgström F., Compston J., Dreinhöfer K., Nolte E., Jonsson L., Lems W. F., McCloskey E. V., Rizzoli R., Stenmark J., SCOPE: a scorecard for osteoporosis in Europe, 10.1007/s11657-013-0144-1
  80. Solomon DH, Johnston SS, Boytsov NN et al. (2014) Osteoporosis medication use after hip fracture in U.S. Patients between 2002 and 2011. J Bone Miner Res
  81. Åkesson K., , Marsh D., Mitchell P. J., McLellan A. R., Stenmark J., Pierroz D. D., Kyer C., Cooper C., Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle, 10.1007/s00198-013-2348-z
Bibliographic reference Kanis, J.A. ; McCloskey, E. ; Branco, J. ; Brandi, M.-L. ; Dennison, E. ; et. al. Goal-directed treatment of osteoporosis in Europe. In: Osteoporosis International : with other metabolic bone diseases, Vol. 25, no. 11, p. 2533-2543 (2014)
Permanent URL http://hdl.handle.net/2078.1/164142